Research Project

Project Title:

Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE).

Project Type:

Clinical Trial, Enrolment ongoing

Disease group(s):

Immune glomerulopathies

Project Summary:

Phase 3, randomized, blinded, multicentre, placebo-controlled study to evaluate the efficacy and safety of Inebilizumab in IgG4-related disease (MITIGATE).

Lead principal investigator(s):

Dario Roccatello, Turin

Project Period:

10/2020   -   12/2060

Sponsors:

Industry

ClinicalTrials.gov:

NCT04540497

« Back to research page